Sort
30,917 grants matching “tumor microenvironment”
BRAVE hydrogels for interrogating cell-matrix interactions in pancreatic desmoplasia
$321,759Chien-Chi Lin · Indiana University Indianapolis · R01 · FY2020 · CA
BRAVE hydrogels for interrogating cell-matrix interactions in pancreatic desmoplasia
$321,759Chien-Chi Lin · Indiana University Indianapolis · R01 · FY2021 · CA
BRAVE hydrogels for interrogating cell-matrix interactions in pancreatic desmoplasia
$321,759Chien-Chi Lin · Indiana University Indianapolis · R01 · FY2022 · CA
Enhancing immune therapy in pancreatic cancer by targeting IL-6
$321,742Gregory B. Lesinski · Emory University · R01 · FY2018 · CA
EPS8 as a Driver of the Oral Cancer Initiating Cell Phenotype.
$321,722William Andrew Yeudall · Augusta University · R01 · FY2017 · DE
IGF-I: A Nutrition-Regulated Target in Prostate Cancer
$321,717Pinchas Cohen · University Of California Los Angeles · R01 · FY2007 · CA
Anti-Tumor immunity in myeloma
$321,696Madhav V Dhodapkar · Yale University · R01 · FY2008 · CA
Targeting the adenosine A2A receptor immune checkpoint in lung cancer patients
$321,654Scott J Antonia · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2016 · CA
Enteric Glia is New Biological Target to Block Drug Resistance in Colon Cancer
$321,629Laurianne Chantal Van Landeghem · North Carolina State University Raleigh · R01 · FY2024 · CA
Targeting the Urokinase Receptor in Glioblastoma Multiforme
$321,625Steven L. Gonias · University Of California, San Diego · R01 · FY2017 · CA
Targeting the Urokinase Receptor in Glioblastoma Multiforme
$321,625Steven L. Gonias · University Of California, San Diego · R01 · FY2015 · CA
Hypoxia and Regulatory T cells in Cancer
$321,625Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2011 · CA
Role of miR-105 in breast cancer metastasis
$321,625Shizhen Emily Wang · University Of California, San Diego · R01 · FY2016 · CA
Exploiting Metabloic Defects in Tumors with Mutant IDH1 and IDH2
$321,625Christian Michael Metallo · University Of California, San Diego · R01 · FY2016 · CA
Exploiting Metabloic Defects in Tumors with Mutant IDH1 and IDH2
$321,625Christian Michael Metallo · University Of California, San Diego · R01 · FY2015 · CA
Eicosanoids in Lung Cancer: Progression and Metastasis
$321,625Raphael A. Nemenoff · University Of Colorado Denver · R01 · FY2015 · CA
Targeting the Urokinase Receptor in Glioblastoma Multiforme
$321,625Steven L. Gonias · University Of California, San Diego · R01 · FY2016 · CA
Exploiting Metabloic Defects in Tumors with Mutant IDH1 and IDH2
$321,625Christian Michael Metallo · University Of California, San Diego · R01 · FY2018 · CA
Exploiting Metabloic Defects in Tumors with Mutant IDH1 and IDH2
$321,625Christian Michael Metallo · University Of California, San Diego · R01 · FY2017 · CA
Exploiting Metabloic Defects in Tumors with Mutant IDH1 and IDH2
$321,625Christian Michael Metallo · University Of California, San Diego · R01 · FY2014 · CA
Project 2: Multi-Omics of high-risk MM
$321,593Esteban Braggio · Mayo Clinic Arizona · P50 · FY2022 · CA
Regulation of the P13K/AKT pathway in Waldenstrom Macroglobulinemia
$321,579Irene M. Ghobrial · Dana-Farber Cancer Inst · R21 · FY2007 · CA
Role of HSP70 in Pancreatic Diseases
$321,544Sundaram Ramakrishnan · University Of Miami School Of Medicine · R01 · FY2022 · CA
Regulation of the P13K/AKT pathway in Waldenstrom Macroglobulinemia
$321,536Irene M. Ghobrial · Dana-Farber Cancer Inst · R21 · FY2008 · CA
Project 1: Arming Oncolytic HSV Vectors to Improve Virolysis in Syngeneic Mouse Models of GBM
$321,473Joseph C. Glorioso · Brigham And Women'S Hospital · P01 · FY2019 · CA